Baxter faces class action lawsuit amid product defects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy BAX?
Source: Globenewswire
Baxter International Inc (BAX) saw a price increase of 3.00%, reaching a 20-day high. This movement occurs amid broader market weakness, with the Nasdaq-100 down 0.27% and the S&P 500 down 0.13%.
The stock's rise comes despite significant legal challenges, as Baxter is facing a class action lawsuit over systemic defects in its Novum LVP devices. The lawsuit alleges that these defects pose serious risks to patients, potentially leading to severe consequences for the company's sales and reputation. Investors are concerned about the implications of this lawsuit, which could lead to increased regulatory scrutiny and legal liabilities for Baxter.
The ongoing legal issues may overshadow the stock's recent performance, indicating that while the price has risen, investor sentiment remains cautious due to the potential financial and reputational impacts of the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 17.460
Low
15.00
Averages
22.13
High
30.00
Current: 17.460
Low
15.00
Averages
22.13
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
"United Health and 8 Additional Dividend Stocks to Weather an Oil Crisis"
- Market Conditions: Crude prices are rising while stock prices are falling, creating uncertainty for investors.
- Investment Strategy: Dividend stocks are suggested as a potential safe haven for investors looking to navigate the current market volatility.
See More
9 Dividend Stocks to Weather an Oil Crisis
- Crude Prices and Market Impact: Crude prices are rising significantly, leading to a decline in stock values, prompting investors to seek safer investment options.
- Stock Sensitivity to Oil Shocks: Not all stocks react the same way to fluctuations in oil prices, indicating that some may offer more stability during these market changes.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Pale Fire Capital Acquires Baxter Shares Worth $39.63 Million
- New Stake Acquisition: Pale Fire Capital disclosed in its SEC filing dated February 13, 2026, that it acquired 2,074,016 shares of Baxter International, with an estimated trade value of $39.63 million, indicating a strong confidence in the healthcare sector.
- Position Value Change: At quarter-end, Baxter's position was valued at $39.63 million, reflecting the dual impact of new share acquisitions and stock price movements, further solidifying its place in the investment portfolio.
- Portfolio Restructuring: Pale Fire Capital significantly increased its investment in healthcare stocks during the fourth quarter, with Baxter being the largest new stock addition, demonstrating a strategic pivot towards the healthcare industry.
- Sales Growth Potential: Despite reporting significant net losses in 2024 and 2025, Baxter's fourth-quarter sales rose by 8% year-over-year, particularly strong in international markets, indicating potential for future recovery.
See More
Pale Fire Capital Acquires Baxter International Shares
- New Investment Dynamics: According to its latest SEC filing dated February 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International (BAX) by purchasing 2,074,016 shares, with an estimated transaction value of $39.63 million, reflecting confidence in the healthcare sector.
- Asset Allocation Shift: Baxter's shares account for 2.66% of Pale Fire Capital SE's $1.49 billion reportable U.S. equity AUM as of December 31, 2025, indicating a strategic focus on healthcare investments by the fund.
- Market Performance Analysis: As of February 13, 2026, Baxter's stock price stood at $19.79, down 34.2% year-over-year, significantly underperforming the S&P 500 by 46 percentage points, suggesting market caution regarding its future growth prospects.
- Financial Overview: Baxter reported $11.24 billion in trailing twelve-month revenue and a net loss of $900 million; however, the 8% growth in fourth-quarter sales from continuing operations, particularly in international markets, indicates potential recovery signs.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
"United Health and 8 Additional Dividend Stocks to Weather an Oil Crisis"
- Market Conditions: Crude prices are rising while stock prices are falling, creating uncertainty for investors.
- Investment Strategy: Dividend stocks are suggested as a potential safe haven for investors looking to navigate the current market volatility.
See More
9 Dividend Stocks to Weather an Oil Crisis
- Crude Prices and Market Impact: Crude prices are rising significantly, leading to a decline in stock values, prompting investors to seek safer investment options.
- Stock Sensitivity to Oil Shocks: Not all stocks react the same way to fluctuations in oil prices, indicating that some may offer more stability during these market changes.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Pale Fire Capital Acquires Baxter Shares Worth $39.63 Million
- New Stake Acquisition: Pale Fire Capital disclosed in its SEC filing dated February 13, 2026, that it acquired 2,074,016 shares of Baxter International, with an estimated trade value of $39.63 million, indicating a strong confidence in the healthcare sector.
- Position Value Change: At quarter-end, Baxter's position was valued at $39.63 million, reflecting the dual impact of new share acquisitions and stock price movements, further solidifying its place in the investment portfolio.
- Portfolio Restructuring: Pale Fire Capital significantly increased its investment in healthcare stocks during the fourth quarter, with Baxter being the largest new stock addition, demonstrating a strategic pivot towards the healthcare industry.
- Sales Growth Potential: Despite reporting significant net losses in 2024 and 2025, Baxter's fourth-quarter sales rose by 8% year-over-year, particularly strong in international markets, indicating potential for future recovery.
See More
Pale Fire Capital Acquires Baxter International Shares
- New Investment Dynamics: According to its latest SEC filing dated February 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International (BAX) by purchasing 2,074,016 shares, with an estimated transaction value of $39.63 million, reflecting confidence in the healthcare sector.
- Asset Allocation Shift: Baxter's shares account for 2.66% of Pale Fire Capital SE's $1.49 billion reportable U.S. equity AUM as of December 31, 2025, indicating a strategic focus on healthcare investments by the fund.
- Market Performance Analysis: As of February 13, 2026, Baxter's stock price stood at $19.79, down 34.2% year-over-year, significantly underperforming the S&P 500 by 46 percentage points, suggesting market caution regarding its future growth prospects.
- Financial Overview: Baxter reported $11.24 billion in trailing twelve-month revenue and a net loss of $900 million; however, the 8% growth in fourth-quarter sales from continuing operations, particularly in international markets, indicates potential recovery signs.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
